Promising Results in Phase III Trial of Novel Kidney Disease Drug
An experimental drug, BI 690517, has shown significant benefits in reducing albuminuria, a sign of kidney damage, in patients with chronic kidney disease. When combined with a standard-care medication, 70% of participants experienced a significant reduction in albuminuria. The drug is designed to inhibit the production of aldosterone, a hormone that accelerates kidney disease progression. The trial also utilized an SGLT2 inhibitor, empagliflozin, which has shown kidney-protective effects. The findings will inform a Phase III clinical trial with 11,000 patient-participants worldwide, potentially revolutionizing the treatment of kidney disease.